{"sequenceId":"845363543150","id":"34207155207","language":"English","title":"GTX (GTXI) Rating Lowered to Sell at Zacks Investment Research","content":"GTX (NASDAQ:GTXI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, May 18th.    According to Zacks, “GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.   “    Get GTX alerts:      Several other analysts also recently issued reports on GTXI. BidaskClub raised shares of GTX from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 26th. ValuEngine upgraded GTX from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Stifel Nicolaus increased their target price on GTX from $16.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, March 5th. Finally, Robert W. Baird  reiterated a “buy” rating and set a $20.00 target price on shares of GTX in a research note on Tuesday, March 6th. One equities research analyst  has rated the stock with a sell rating, three have issued  a buy rating and one  has assigned  a strong buy rating to the stock. GTX currently has a consensus rating of “Buy” and a consensus target price of $37.50.      Shares of GTX traded down $0.01, hitting $20.19, during trading hours on Friday, Marketbeat reports. 107,612 shares of the company were exchanged, compared to its average volume of 187,504. The firm has a market cap of $470.42 million, a P/E ratio of -11.54 and a beta of 1.60. GTX has a 1 year low of $2.73 and a 1 year high of $23.40.    GTX (NASDAQ:GTXI) last issued its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.19).  equities analysts expect that  GTX will post -1.87 earnings per share for the current year.    Several institutional investors have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP purchased a new position in shares of  GTX during the 1st quarter valued at approximately $6,284,000.  Millennium Management LLC lifted its stake in  GTX by 107.0% during the first quarter. Millennium Management LLC now owns 121,957 shares of the biopharmaceutical company’s stock worth $2,165,000 after purchasing an additional 63,051 shares during the last quarter.  Point72 Asset Management L.P. bought a new position in  GTX during the first quarter worth $1,917,000.  Federated Investors Inc. PA bought a new position in  GTX during the first quarter worth $1,558,000.  Finally, EAM Investors LLC bought a new position in  GTX during the fourth quarter worth $551,000. Institutional investors own  21.74% of the company’s stock.    GTX Company Profile    GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.       For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"GTX (NASDAQ:GTXI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, May 18th.    According to Zacks, “GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.   “    Get GTX alerts:      Several other analysts also recently issued reports on GTXI. BidaskClub raised shares of GTX from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 26th. ValuEngine upgraded GTX from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Stifel Nicolaus increased their target price on GTX from $16.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, March 5th. Finally, Robert W. Baird  reiterated a “buy” rating and set a $20.00 target price on shares of GTX in a research note on Tuesday, March 6th. One equities research analyst  has rated the stock with a sell rating, three have issued  a buy rating and one  has assigned  a strong buy rating to the stock. GTX currently has a consensus rating of “Buy” and a consensus target price of $37.50.      Shares of GTX traded down $0.01, hitting $20.19, during trading hours on Friday, Marketbeat reports. 107,612 shares of the company were exchanged, compared to its average volume of 187,504. The firm has a market cap of $470.42 million, a P/E ratio of -11.54 and a beta of 1.60. GTX has a 1 year low of $2.73 and a 1 year high of $23.40.    GTX (NASDAQ:GTXI) last issued its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.19).  equities analysts expect that  GTX will post -1.87 earnings per share for the current year.    Several institutional investors have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP purchased a new position in shares of  GTX during the 1st quarter valued at approximately $6,284,000.  Millennium Management LLC lifted its stake in  GTX by 107.0% during the first quarter. Millennium Management LLC now owns 121,957 shares of the biopharmaceutical company’s stock worth $2,165,000 after purchasing an additional 63,051 shares during the last quarter.  Point72 Asset Management L.P. bought a new position in  GTX during the first quarter worth $1,917,000.  Federated Investors Inc. PA bought a new position in  GTX during the first quarter worth $1,558,000.  Finally, EAM Investors LLC bought a new position in  GTX during the fourth quarter worth $551,000. Institutional investors own  21.74% of the company’s stock.    GTX Company Profile    GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.       For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-03T03:31:00Z","harvestDate":"2018-06-02T21:35:22Z","estimatedPublishedDate":"2018-06-02T21:35:22Z","url":"http://ct.moreover.com/?a=34207155207&p=1u0&v=1&x=3TfPUhIzfnhl8FJhgSq9eg","originalUrl":"https://ledgergazette.com/2018/06/02/gtx-gtxi-downgraded-by-zacks-investment-research-to-sell-2.html","outboundUrls":["http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=GTXI","https://www.marketbeat.com/"],"wordCount":"564","dataFormat":"text","duplicateGroupId":"34207155207","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Business latest","group":"Business"}],"companies":[{"name":"Federated Investors Inc","symbol":"3KC","exchange":"DUS","isin":"US3142111034","titleCount":0,"contentCount":2,"primary":true},{"name":"Federated Investors Inc","symbol":"3KC","exchange":"FRA","isin":"US3142111034","titleCount":0,"contentCount":2,"primary":true},{"name":"Federated Investors Inc","symbol":"FII","exchange":"NYS","isin":"US3142111034","titleCount":0,"contentCount":2,"primary":true},{"name":"GTx Inc","symbol":"GTXI","exchange":"NAS","isin":"US40052B2079","titleCount":0,"contentCount":2,"primary":true},{"name":"GTx Inc","symbol":"GTU1","exchange":"FRA","isin":"US40052B2079","titleCount":0,"contentCount":2,"primary":true},{"name":"GTx Inc","symbol":"GTU1","exchange":"MUN","isin":"US40052B2079","titleCount":0,"contentCount":2,"primary":true},{"name":"GTx Inc","symbol":"GTU1","exchange":"STU","isin":"US40052B2079","titleCount":0,"contentCount":2,"primary":true},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"FRA","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"MUN","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"NYS","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"TSE","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI.PR.B","exchange":"TSE","isin":"CA8849033037","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Joyce Ramirez","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Ledger Gazette","homeUrl":"https://ledgergazette.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"599564993","name":"Ledger Gazette","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1137"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Business"],"genre":"General"}},"es_id":86991814}